How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/acute-exacerbation-of-chronic-bronchitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Acute exacerbation of chronic bronchitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acute exacerbation of chronic bronchitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Acute exacerbation of chronic bronchitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Factive	GEMIFLOXACIN MESYLATE	Lg Chem Ltd	Quinolone Antimicrobial		2003-01-01
Zymar	GATIFLOXACIN	Allergan		DNA gyrase, DNA gyrase, DNA gyrase subunit A	2003-01-01
Factive	GEMIFLOXACIN	Lg Chem Ltd	Quinolone Antimicrobial		2003-01-01
Cefditoren Pivoxyl	CEFDITOREN PIVOXIL	Vansen Pharma	Cephalosporin Antibacterial		2001-01-01
Avelox	moxifloxacin	Bayer AG	Fluoroquinolone antibiotic (fourth-generation)	DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A	1999-12-10
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20
Zithromax	azithromycin	Pfizer Inc.	Macrolide antibiotic (azalide)	Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor	1991-11-01
Biaxin	clarithromycin	Generic (originally Abbott/AbbVie)	Macrolide Antimicrobial [EPC]	Potassium voltage-gated channel subfamily H member 2	1991-10-31
Cefzil	cefprozil	Teva Pharmaceuticals USA	Cephalosporin Antibacterial [EPC]		1991-01-01
Ceftin	CEFUROXIME AXETIL	GSK	Cephalosporin Antibacterial		1987-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 6 drugs in Acute exacerbation of chronic bronchitis
Lg Chem Ltd · 2 drugs in Acute exacerbation of chronic bronchitis
GSK · 2 drugs in Acute exacerbation of chronic bronchitis
Bayer AG · 1 drug in Acute exacerbation of chronic bronchitis
Bristol-Myers Squibb · 1 drug in Acute exacerbation of chronic bronchitis
Dr Reddys Labs Sa · 1 drug in Acute exacerbation of chronic bronchitis
Generic (originally Abbott/AbbVie) · 1 drug in Acute exacerbation of chronic bronchitis
Generic (originally Beecham/GSK) · 1 drug in Acute exacerbation of chronic bronchitis
Generic (originally Daiichi Sankyo/J&J) · 1 drug in Acute exacerbation of chronic bronchitis
King George's Medical University · 1 drug in Acute exacerbation of chronic bronchitis
Merck & Co. · 1 drug in Acute exacerbation of chronic bronchitis
Merck Sharp & Dohme B.V. · 1 drug in Acute exacerbation of chronic bronchitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Acute exacerbation of chronic bronchitis:

Cite this brief

Drug Landscape (2026). Acute exacerbation of chronic bronchitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acute-exacerbation-of-chronic-bronchitis. Accessed 2026-06-10.

Acute exacerbation of chronic bronchitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing